Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Минеральная плотность костей у больных раком молочной железы
Минеральная плотность костей у больных раком молочной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представлен обзор литературы по результатам клинических исследований состояния минеральной плотности костей (МПК) у больных раком молочной железы (РМЖ). Приведены данные о значительном изменении МПК у больных РМЖ после проведения адъювантной химиотерапии и эндокринотерапии. Отражено значение менструального статуса, вариантов гормонотерапии на состояние МПК у больных РМЖ. Показана эффективность назначения бисфосфонатов для профилактики снижения МПК у больных РМЖ. Представлены данные о большей эффективности немедленного назначения бисфосфонатов против отсроченного назначения. Отражены текущие алгоритмы назначения бисфосфонатов у больных РМЖ для профилактики снижения МПК.
Ключевые слова: рак молочной железы, минеральная плотность костей, бисфосфонаты, тамоксифен, ингибиторы ароматазы, зомета.
Key words: breast cancer, bone mineral density, bisphosphonates, tamoxifen and aromatase inhibitors, zometa.
Ключевые слова: рак молочной железы, минеральная плотность костей, бисфосфонаты, тамоксифен, ингибиторы ароматазы, зомета.
________________________________________________
Key words: breast cancer, bone mineral density, bisphosphonates, tamoxifen and aromatase inhibitors, zometa.
Полный текст
Список литературы
1. Поддубная И.В., Колядина И.В., Трофимова О.П. и др. Прогностическое значение локального и системного лечения при раке молочной железы I стадии. Соврем. онкология. 2013; 3: 33–40.
2. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
3. Baum M, Hackshaw A, Houghton J et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006; 42: 895–904.
4. Body JJ, Bergmann P, Boonen S et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer – a consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18: 1439–50.
5. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784–96.
6. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8: 119–27.
7. Cooke AL, Metge C, Lix L et al. Tamoxifen use and osteoporotic fracture risk: A population-based analysis. J Clin Oncol 2008; 26: 5227–32.
8. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA 2002; 288: 1889–97.
9. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73.
10. Cuzick J, Ambroisine L, Davidson N et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptorpositive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711–23.
11. David M, Reid A, Doughty JB et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews 2008; 34: s3.
12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687–717.
13. Eastell R, Adams JE, Coleman RE et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole Tamoxifen Alone or in Combination Trial 18233230. J Clin Oncol 2008; 26: 1051–7.
14. Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188–94.
15. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
16. Faulkner KG. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183–7.
17. Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95: 75–81.
18. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820–8.
19. Good PJ, Ennis M, Pritchard KI et al. Prognostic effects of 25-hydroxyvitamin D Leveis in early breast cancer. J Clin Oncol 2009; 27: 3757–63.
20. Azim HA, Azambuja JE, Colozza M et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncology 2011; 22: 1939–47.
21. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57.
22. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490–5.
23. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 year’s adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
24. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2009; 59: 225–49.
25. Lester JE, Dodwell D, Horsman JM et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006; 94: 30–5.
26. Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336–42.
27. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006; 6: 1041–50.
28. Love RR, Mazess RB, Barden HS et al. Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6.
29. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9.
30. National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htm
31. Pacifici R. Estrogen cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.
32. Park-Wyllie L, Mamdani M, Juurlink D et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–9.
33. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole vs placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. J Clin Oncol 2006; 24: 3629–35.
34. Plevritis SK, Fryback DG, Clarke L et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784–92.
35. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84.
36. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733–59.
37. Simpson ER, Dowsett M. Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 2002; 57: 317–38.
38. Syed Z, Khan A. Bone densitometry: Applications and limitations. J Obstet Gynaecol Can 2002; 24: 476–84.
39. Thürlimann B, Keshaviah A, Coates AS et al. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.
40. Valachis A, Polyzos NP, Georgoulias V et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol 2010; 117: 139–45.
41. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 2010; 28: 967–75.
42. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24 (4): 675–80.
43. Warne GT, Failey KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159–62.
44. Warne GT, Failey KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159–62.
45. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006; 116: 1186–94.
2. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
3. Baum M, Hackshaw A, Houghton J et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006; 42: 895–904.
4. Body JJ, Bergmann P, Boonen S et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer – a consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18: 1439–50.
5. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784–96.
6. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8: 119–27.
7. Cooke AL, Metge C, Lix L et al. Tamoxifen use and osteoporotic fracture risk: A population-based analysis. J Clin Oncol 2008; 26: 5227–32.
8. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA 2002; 288: 1889–97.
9. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73.
10. Cuzick J, Ambroisine L, Davidson N et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptorpositive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711–23.
11. David M, Reid A, Doughty JB et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews 2008; 34: s3.
12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687–717.
13. Eastell R, Adams JE, Coleman RE et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole Tamoxifen Alone or in Combination Trial 18233230. J Clin Oncol 2008; 26: 1051–7.
14. Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188–94.
15. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
16. Faulkner KG. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183–7.
17. Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95: 75–81.
18. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820–8.
19. Good PJ, Ennis M, Pritchard KI et al. Prognostic effects of 25-hydroxyvitamin D Leveis in early breast cancer. J Clin Oncol 2009; 27: 3757–63.
20. Azim HA, Azambuja JE, Colozza M et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncology 2011; 22: 1939–47.
21. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57.
22. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490–5.
23. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 year’s adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
24. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2009; 59: 225–49.
25. Lester JE, Dodwell D, Horsman JM et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006; 94: 30–5.
26. Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336–42.
27. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006; 6: 1041–50.
28. Love RR, Mazess RB, Barden HS et al. Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6.
29. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9.
30. National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htm
31. Pacifici R. Estrogen cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.
32. Park-Wyllie L, Mamdani M, Juurlink D et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–9.
33. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole vs placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. J Clin Oncol 2006; 24: 3629–35.
34. Plevritis SK, Fryback DG, Clarke L et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784–92.
35. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84.
36. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733–59.
37. Simpson ER, Dowsett M. Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 2002; 57: 317–38.
38. Syed Z, Khan A. Bone densitometry: Applications and limitations. J Obstet Gynaecol Can 2002; 24: 476–84.
39. Thürlimann B, Keshaviah A, Coates AS et al. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.
40. Valachis A, Polyzos NP, Georgoulias V et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol 2010; 117: 139–45.
41. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 2010; 28: 967–75.
42. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24 (4): 675–80.
43. Warne GT, Failey KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159–62.
44. Warne GT, Failey KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159–62.
45. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006; 116: 1186–94.
Авторы
И.В.Поддубная, Е.В.Кижаев, И.В.Колядина, С.М.Банов, Е.М.Жмаева, М.А.Сецко
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.